%0 Journal Article
%T China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
%A Dongmei Chen
%A Hong Zhang
%A Jianhong Pan
%A Limin Zou
%A Lin Xia
%A Ling Tang
%A Ming Zhou
%A Rong Gao
%A Ruimin Hao
%A Xiao Zhao
%A Xiaoyuan Chen
%A Xin Tong
%A Yuankai Shi
%A Yuanyuan Song
%A Yueli Qi
%A Zhifang Liu
%A Zhimin Yang
%J Archive of "Cancer Communications".
%D 2019
%R 10.1186/s40880-019-0383-7
%X Study design of the ALTER0303 trial. NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor recepto
%K Advanced non-small cell lung cancer
%K Anlotinib
%K Anti-angiogenesis
%K Epidermal growth factor receptor
%K Activating anaplastic lymphoma kinase
%K Adverse drug reaction
%K National Medical Products Administration
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585030/